Table 4:
Policy scenarios to scale-up availability of treatment/imaging modalities to the mean level of high-income countries
| Scale-up to mean of high-income countries | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumulative Scale-up Scenarios |
Treatment | Imaging | Estimated global breast cancer 5- year net survival (%), mean (95% UI) |
|||||||||
| Chemo- therapy |
Radio- therapy |
Surgery | Targeted therapy |
Quality of care |
Ultra- sound |
X-ray | CT | MRI | SPECT | PET | ||
| Baseline (status quo) | 67·9 (62·9-73·4) | |||||||||||
| + Treatment (traditional) | X | X | X | 74·4 (69·9-78·2) | ||||||||
| + Imaging (traditional) | X | X | X | X | X | 75·6 (70·6-79·4) | ||||||
| + Quality | X | X | X | X | X | X | 78·2 (74·9-80·4) | |||||
| + Targeted Therapy | X | X | X | X | X | X | X | 79·1 (75·7-81·4) | ||||
| + CT | X | X | X | X | X | X | X | X | 79·6 (76·3-82·1) | |||
| + MRI | X | X | X | X | X | X | X | X | X | 80·6 (76·3-82·1) | ||
| + SPECT | X | X | X | X | X | X | X | X | X | X | 81·2 (78·7-84·2) | |
| + PET | X | X | X | X | X | X | X | X | X | X | X | 82·3 (79·3-85·0) |